Therapy/Class:
Levocetirizine:
Therapy: Anti-Allergic
Class: Second Generation Antihistamines
Montelukast:
Therapy: Anti-Allergic
Class: Leukotriene receptor antagonist (LTRA)
Mechanism of Action:
Levocetirizine: It is a highly selective for histamine H1-receptors & competes with free histamine for binding at H1-receptor sites. This competitive antagonism blocks the effects of histamine on H1-receptors in the GI tract, large blood vessels, and bronchial smooth muscle. Blockade of H1-receptors also suppresses the formation of edema, flare, and pruritus that result from histaminic activity. It also has anti-inflammatory action related to a reduction in eosinophils, neutrophils, interleukin-4 and interleukin-8.
Montelukast: It bind & act as Antagonists to cysteinyl leukotriene (CysLT) receptor found in the human airway including airway smooth muscle cells and airway macrophages. CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis.
Indications:
- Alleviation of symptoms associated with allergic rhinitis, whether it’s seasonal or perennial.
- Prophylactic treatment for seasonal allergic rhinitis.
- Management of bronchial asthma and bronchitis.
Dosage & Administration:
For Children aged 6 to 11 Yrs:
Dispersible Tablet: One Tablet in the evening
Syrup: 5ml in the evening
For Children aged 2 to 6 Yrs:
Dispersible Tablet: Half Tablet in the evening
Syrup: 2.5ml in the evening
HOW SUPPLIED: TINYMONT-LC KID SYRUP is available as Syrup 60ml Pack.
References:
- May BC, Gallivan KH. Levocetirizine and montelukast in the COVID-19 treatment paradigm. Int Immunopharmacol. 2022 Feb;103:108412. doi: 10.1016/j.intimp.2021.108412. Epub 2021 Dec 15.
- J Aller Ther 1:103. doi:10.4172/2155-6121.1000103
- Indian J Pharmacol. 2016 Nov-Dec; 48(6): 649–653.
